07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Development halted

Adocia said it will halt development of BioChaperone PDGF-BB to treat diabetic foot ulcers after top-line data from a double-blind, Indian Phase III trial in 252 patients showed that 4 ug/cm 2 BioChaperone PDGF-BB spray...
07:00 , Aug 26, 2016 |  BC Extra  |  Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Phase III started

Adocia began a double-blind, placebo-controlled, Indian Phase III trial to evaluate BioChaperone PDGF-BB spray in 252 Type I and II diabetics with a chronic foot ulcer. In 4Q15, the company also plans to start a...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Phase III start

Adocia said it received positive scientific advice from EMA for a placebo-controlled, European Phase III trial of BioChaperone PDGF-BB. The trial is slated to start mid-2014. According to Adocia, EMA said 1 European Phase III...
08:00 , Feb 20, 2012 |  BioCentury  |  Finance

Bon appétit

Strong demand for the first European biotech IPO of the year may signal an increased appetite for risk from European investors. It also meant venture investors in Adocia S.A.S. did not have to put nearly...
01:40 , Feb 17, 2012 |  BC Extra  |  Top Story

Adocia raises EUR 25.3 million in IPO

Adocia S.A. (Lyon, France) raised EUR 25.3 million ($33.6 million) through the sale of 1.6 million shares at EUR 15.88 in an IPO on Euronext Paris and private placement outside the U.S. The price values...
08:00 , Jan 30, 2012 |  BioCentury  |  Finance

Euronext door opener

Euronext door opener The first European biotech IPO of 2012 looks to be French polymer play Adocia S.A.S. , which announced details of its deal on Euronext Paris and a private placement outside the U.S....
01:32 , Jan 28, 2012 |  BC Extra  |  Financial News

French polymer company Adocia releases IPO details

Adocia S.A.S. (Lyon, France) unveiled details of its planned IPO on Euronext Paris and private placement outside the U.S. The company hopes to sell 1.4 million shares at EUR 13-EUR 15.88. If sold in full...
01:34 , Jan 19, 2012 |  BC Extra  |  Financial News

French polymer company Adocia planning IPO

Adocia S.A.S. (Lyon, France) is planning an IPO on Euronext Paris. Adocia is preparing for Phase III testing of BioChaperone PDGF-BB for diabetic foot ulcers. The product is a recombinant platelet derived growth factor BB...